This HTML5 document contains 44 embedded RDF statements represented using HTML+Microdata notation.

The embedded RDF content will be recognized by any processor of HTML5 Microdata.

Namespace Prefixes

PrefixIRI
dctermshttp://purl.org/dc/terms/
n13http://localhost/temp/predkladatel/
n10http://linked.opendata.cz/resource/domain/vavai/riv/tvurce/
n7http://linked.opendata.cz/resource/domain/vavai/projekt/
n6http://linked.opendata.cz/resource/domain/vavai/subjekt/
n5http://linked.opendata.cz/ontology/domain/vavai/
n11http://linked.opendata.cz/resource/domain/vavai/zamer/
n21http://linked.opendata.cz/resource/domain/vavai/vysledek/RIV%2F00216208%3A11120%2F12%3A43904240%21RIV13-MSM-11120___/
shttp://schema.org/
skoshttp://www.w3.org/2004/02/skos/core#
n3http://linked.opendata.cz/ontology/domain/vavai/riv/
n20http://bibframe.org/vocab/
n2http://linked.opendata.cz/resource/domain/vavai/vysledek/
rdfhttp://www.w3.org/1999/02/22-rdf-syntax-ns#
n4http://linked.opendata.cz/ontology/domain/vavai/riv/klicoveSlovo/
n14http://linked.opendata.cz/ontology/domain/vavai/riv/duvernostUdaju/
xsdhhttp://www.w3.org/2001/XMLSchema#
n19http://linked.opendata.cz/ontology/domain/vavai/riv/jazykVysledku/
n16http://linked.opendata.cz/ontology/domain/vavai/riv/aktivita/
n17http://linked.opendata.cz/ontology/domain/vavai/riv/druhVysledku/
n12http://linked.opendata.cz/ontology/domain/vavai/riv/obor/
n15http://reference.data.gov.uk/id/gregorian-year/

Statements

Subject Item
n2:RIV%2F00216208%3A11120%2F12%3A43904240%21RIV13-MSM-11120___
rdf:type
skos:Concept n5:Vysledek
dcterms:description
Nimotuzumab (h-R3) is a humanized monoclonal antibody (mAb) which recognizes the external domain of the epidermal growth factor receptor (EGFR) with high specificity. It was demonstrated that h-R3 has a unique clinical profile for immunotherapy of adult gliomas and pediatric pontine gliomas. The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGFR. Nimotuzumab (h-R3) is a humanized monoclonal antibody (mAb) which recognizes the external domain of the epidermal growth factor receptor (EGFR) with high specificity. It was demonstrated that h-R3 has a unique clinical profile for immunotherapy of adult gliomas and pediatric pontine gliomas. The aim of this work was to evaluate the conjugate (177)Lu-h-R3 as a potential radioimmunoconjugate for radioimmunotherapy (RIT) of tumors overexpressing EGFR.
dcterms:title
Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors
skos:prefLabel
Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors Preparation and preclinical evaluation of 177Lu-nimotuzumab targeting epidermal growth factor receptor overexpressing tumors
skos:notation
RIV/00216208:11120/12:43904240!RIV13-MSM-11120___
n5:predkladatel
n6:orjk%3A11120
n3:aktivita
n16:V n16:Z n16:P
n3:aktivity
P(2B06165), V, Z(AV0Z10480505)
n3:cisloPeriodika
1
n3:dodaniDat
n15:2013
n3:domaciTvurceVysledku
n10:7345623
n3:druhVysledku
n17:J
n3:duvernostUdaju
n14:S
n3:entitaPredkladatele
n21:predkladatel
n3:idSjednocenehoVysledku
161324
n3:idVysledku
RIV/00216208:11120/12:43904240
n3:jazykVysledku
n19:eng
n3:klicovaSlova
Monoclonal antibody; 177Lu; Nimotuzumab; Radioimmunotherapy
n3:klicoveSlovo
n4:Monoclonal%20antibody n4:Radioimmunotherapy n4:Nimotuzumab n4:177Lu
n3:kodStatuVydavatele
US - Spojené státy americké
n3:kontrolniKodProRIV
[3AC20102CFD0]
n3:nazevZdroje
Nuclear Medicine and Biology
n3:obor
n12:FD
n3:pocetDomacichTvurcuVysledku
1
n3:pocetTvurcuVysledku
6
n3:projekt
n7:2B06165
n3:rokUplatneniVysledku
n15:2012
n3:svazekPeriodika
39
n3:tvurceVysledku
Melichar, František
n3:wos
000298936200002
n3:zamer
n11:AV0Z10480505
s:issn
0969-8051
s:numberOfPages
11
n20:doi
10.1016/j.nucmedbio.2011.07.001
n13:organizacniJednotka
11120